Before the lunch break on July 9 at the 2026 Value Investing Seminar in Puglia, Glenn Tongue took the podium to pitch two very different opportunities: a large-cap compounder most of the world already uses every day, and a distressed microcap analytics company he believed was days away from a forced sale. Tongue is President of Kase Learning and founder of Deerhaven Capital Management, and spent 17 years on Wall Street before moving into investing, most recently as a Managing Director and Head of Acquisition Finance at UBS. He holds an MBA from Wharton and sits on the board of Marketwise, the public parent of Stansberry Research, whose branding appeared on his slides. His core argument across both ideas was the same: the market misprices dislocation events, and the patient investor who reads the situation carefully gets paid.
Stock Is Down 44 Percent and the Business Has Never Been Stronger
Tongue opened with the stock stock calling it his favorite blue-chip stock and describing it as a textbook example of what Warren Buffett would call a wonderful business at a fair price. The slide behind him carried a long-run price chart and a pointed subtitle: from its all-time high of $134 just over a year ago, the stock is down 44 percent.

